MC
GSK icon

Moors & Cabot’s GSK GSK Stock Holding History

Moors & Cabot’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.1M Sell
20,980
-492
-2% -$26K 0.04% 361
2026
Q1 		$1.19M Sell
21,472
-1,251
-6% -$67.8K 0.05% 333
2025
Q4 		$1.11M Sell
22,723
-804
-3% -$37.5K 0.05% 334
2025
Q3 		$1.02M Sell
23,527
-1,268
-5% -$49.5K 0.04% 356
2025
Q2 		$952K Sell
24,795
-683
-3% -$26.1K 0.04% 350
2025
Q1 		$987K Sell
25,478
-1,132
-4% -$41.4K 0.05% 327
2024
Q4 		$900K Sell
26,610
-389
-1% -$14K 0.04% 353
2024
Q3 		$1.1M Sell
26,999
-255
-0.9% -$10.4K 0.05% 310
2024
Q2 		$1.05M Buy
27,254
+1,559
+6% +$65.6K 0.06% 297
2024
Q1 		$1.1M Sell
25,695
-1,267
-5% -$52.3K 0.06% 286
2023
Q4 		$999K Sell
26,962
-1,783
-6% -$64K 0.06% 284
2023
Q3 		$1.04M Sell
28,745
-1,859
-6% -$66K 0.07% 254
2023
Q2 		$1.09M Buy
30,604
+500
+2% +$17.9K 0.07% 253
2023
Q1 		$1.07M Sell
30,104
-1,080
-3% -$37.8K 0.07% 254
2022
Q4 		$1.1M Sell
31,184
-156
-0.5% -$5.2K 0.08% 253
2022
Q3 		$922K Sell
31,340
-4,238
-12% -$161K 0.07% 271
2022
Q2 		$1.94M Sell
35,578
-310
-0.9% -$17.1K 0.14% 162
2022
Q1 		$1.95M Buy
35,888
+825
+2% +$44.8K 0.12% 176
2021
Q4 		$1.93M Buy
35,063
+1,706
+5% +$88.7K 0.12% 172
2021
Q3 		$1.6M Buy
33,357
+651
+2% +$32.7K 0.1% 195
2021
Q2 		$1.63M Buy
32,706
+5,336
+19% +$256K 0.11% 178
2021
Q1 		$1.23M Sell
27,370
-1,072
-4% -$48.7K 0.09% 209
2020
Q4 		$1.31M Sell
28,442
-1,583
-5% -$72.7K 0.11% 189
2020
Q3 		$1.41M Buy
30,025
+744
+3% +$37.3K 0.13% 155
2020
Q2 		$1.48M Buy
29,281
+3,381
+13% +$173K 0.16% 141
2020
Q1 		$1.23M Sell
25,900
-5,352
-17% -$285K 0.18% 122
2019
Q4 		$1.83M Sell
31,252
-577
-2% -$32.1K 0.18% 126
2019
Q3 		$1.7M Buy
31,829
+648
+2% +$33.3K 0.19% 131
2019
Q2 		$1.56M Buy
31,181
+61
+0.2% +$3.06K 0.2% 124
2019
Q1 		$1.62M Sell
31,120
-1,351
-4% -$67.5K 0.22% 116
2018
Q4 		$1.56M Sell
32,471
-3,993
-11% -$197K 0.24% 106
2018
Q3 		$1.82M Sell
36,464
-344
-0.9% -$17.5K 0.22% 111
2018
Q2 		$1.84M Sell
36,808
-250
-0.7% -$12.6K 0.25% 105
2018
Q1 		$1.81M Buy
37,058
+11,141
+43% +$519K 0.24% 112
2017
Q4 		$1.16M Sell
25,917
-7,284
-22% -$336K 0.15% 153
2017
Q3 		$1.67M Sell
33,201
-1,726
-5% -$87.6K 0.24% 116
2017
Q2 		$1.9M Sell
34,927
-618
-2% -$32.9K 0.32% 87
2017
Q1 		$1.87M Sell
35,545
-548
-2% -$27.8K 0.32% 90
2016
Q4 		$1.75M Buy
36,093
+1,053
+3% +$52K 0.29% 95
2016
Q3 		$1.9M Buy
35,040
+1,713
+5% +$93.9K 0.32% 81
2016
Q2 		$1.82M Buy
33,327
+8,065
+32% +$425K 0.32% 76
2016
Q1 		$1.27M Buy
25,262
+3,104
+14% +$155K 0.23% 113
2015
Q4 		$1.11M Sell
22,158
-1,433
-6% -$73K 0.2% 134
2015
Q3 		$1.14M Sell
23,591
-5,617
-19% -$292K 0.21% 129
2015
Q2 		$1.52M Sell
29,208
-7,564
-21% -$426K 0.25% 103
2015
Q1 		$2.12M Buy
36,772
+786
+2% +$45.1K 0.35% 75
2014
Q4 		$1.91M Buy
35,986
+1,714
+5% +$95.9K 0.32% 84
2014
Q3 		$1.97M Buy
34,272
+17,950
+110% +$1.1M 0.34% 73
2014
Q2 		$1.09M Buy
16,322
+469
+3% +$31.7K 0.18% 128
2014
Q1 		$1.06M Buy
+15,853
New +$1.07M 0.27% 101

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Moors & Cabot's GSK Position: Q2 2026 in Review

Moors & Cabot reduced its GSK (GSK) stake by 2.3% in Q2 2026, selling an estimated $26K and leaving 20,980 shares worth $1.1M. The position accounts for 0.04% of the portfolio, ranked #361.

Moors & Cabot first reported a position in GSK in Q1 2014 and has held it in 50 quarters since. The position peaked at $2.12M in Q1 2015. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Moors & Cabot held 20,980 shares of GSK worth $1.1M as of Q2 2026.
  • Moors & Cabot sold 492 GSK shares in Q2 2026, an estimated $26K.
  • GSK made up 0.04% of Moors & Cabot's portfolio in Q2 2026, its #361 holding.
  • Moors & Cabot first reported a position in GSK in Q1 2014 and has held it in 50 quarters since.
  • Moors & Cabot's GSK position peaked at $2.12M in Q1 2015.
  • 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Moors & Cabot's 13F filing for Q2 2026, filed 10 Aug 2026.